1. Home
  2. MYGN vs NCV Comparison

MYGN vs NCV Comparison

Compare MYGN & NCV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Myriad Genetics Inc.

MYGN

Myriad Genetics Inc.

HOLD

Current Price

$4.00

Market Cap

372.1M

Sector

Health Care

ML Signal

HOLD

Logo Virtus Convertible & Income Fund of Beneficial Interest

NCV

Virtus Convertible & Income Fund of Beneficial Interest

HOLD

Current Price

$16.17

Market Cap

373.7M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
MYGN
NCV
Founded
1991
2003
Country
United States
United States
Employees
2700
N/A
Industry
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Finance Companies
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
372.1M
373.7M
IPO Year
1996
N/A

Fundamental Metrics

Financial Performance
Metric
MYGN
NCV
Price
$4.00
$16.17
Analyst Decision
Buy
Analyst Count
7
0
Target Price
$7.64
N/A
AVG Volume (30 Days)
1.9M
55.7K
Earning Date
05-05-2026
01-01-0001
Dividend Yield
N/A
12.48%
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$771,400,000.00
N/A
Revenue This Year
$6.86
N/A
Revenue Next Year
$5.45
N/A
P/E Ratio
N/A
N/A
Revenue Growth
2.33
N/A
52 Week Low
$2.74
$14.46
52 Week High
$8.59
$17.65

Technical Indicators

Market Signals
Indicator
MYGN
NCV
Relative Strength Index (RSI) 59.98 43.17
Support Level $2.89 $15.55
Resistance Level $5.42 $16.28
Average True Range (ATR) 0.24 0.31
MACD 0.14 -0.02
Stochastic Oscillator 85.20 50.79

Price Performance

Historical Comparison
MYGN
NCV

About MYGN Myriad Genetics Inc.

Myriad Genetics Inc is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. The company develops and commercializes molecular tests that help patients and providers uncover genetic insights. Its tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties, supporting earlier detection, more precise treatment, and lowering healthcare costs. Its tests include BRACAnalysis CDx, EndoPredict, FirstGene, Foresight, GeneSight, MyChoice CDx, MyRisk (cancer treatment), MyRisk (cancer risk), Prequel, Precise Tumor, Prolaris, and SneakPeek. The company operates in the US and Rest of World, with maximum revenue from the US.

About NCV Virtus Convertible & Income Fund of Beneficial Interest

Virtus Convertible & Income Fund is a diversified, closed-end management investment company. Its investment objective is to provide total return through a combination of current income, current gains and long-term capital appreciation. It intends to achieve the objective by investing in a portfolio of domestic convertible securities and non-convertible income-producing securities. Its portfolio of investments includes Software, the Internet, the Commercial Services sector in the form of Convertible Bonds and Notes, and Media, Oil, Gas & Consumable Fuels, and Entertainment sector in the form of Corporate Bonds and Notes.

Share on Social Networks: